Clinical Trials Logo

HER-2 Gene Amplification clinical trials

View clinical trials related to HER-2 Gene Amplification.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05511844 Recruiting - Clinical trials for HER2-positive Breast Cancer

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Start date: October 3, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.

NCT ID: NCT05318339 Recruiting - Clinical trials for Carcinoma, Transitional Cell

A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

Start date: March 10, 2022
Phase: Phase 2
Study type: Interventional

A open-label, single-arm, phase II trial to study was designed to evaluate the effectiveness and safety of trastuzumab and pyrotinib in treating HER2 positive patients who have previously treated, locally advanced, or metastatic urothelial carcinoma.

NCT ID: NCT05170256 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients

HERES
Start date: February 4, 2022
Phase: Phase 2
Study type: Interventional

The study aims to determine the efficacy of trastuzumab added to standard treatment (fluoropyrimidine/platinum doublet with pembrolizumab) in patients with HER2 positive Esophageal squamous cell carcinoma (ESCC) determined by 6 months progression free survival (PFS) (RECIST 1.1).

NCT ID: NCT03979911 Recruiting - Breast Neoplasms Clinical Trials

Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer

EPTTCSM
Start date: January 22, 2019
Phase:
Study type: Observational

This retrospective study evaluated the efficacy and the safety of use of this treatment combined with a taxane for the treatment of HER2-positive metastatic breast cancer and compared the clinical and demographic characteristics of real life patients to the patients of CLEOPATRA.